KOMBIGLYZE XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Nov 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KOMBIGLYZE XR is a fixed-dose combination tablet containing saxagliptin (a dipeptidyl peptidase-4 inhibitor) and metformin hydrochloride (an extended-release biguanide) for oral administration. It is indicated for the treatment of type 2 diabetes mellitus in patients requiring dual therapy. The combination works through dual mechanisms: saxagliptin enhances insulin secretion by inhibiting DPP-4, while metformin reduces hepatic glucose production and improves insulin sensitivity. It represents a convenient single-tablet option for patients inadequately controlled on monotherapy.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Korean Post-marketing Surveillance for Kombiglyze XR®
Started Nov 2012
755 enrolled
Diabetes Mellitus, Type 2
Career Relevance
918 roles are currently linked to this product, spanning brand management, field sales, medical science liaisons, market access, and regulatory positions. Career roles focus on managing the transition during exclusivity loss, preparing for generic competition, and maintaining market share through formulary management and healthcare provider engagement. Skills in managed care strategy, generic transition planning, and cost-containment positioning are particularly valuable as the product approaches LOE.
Company
Worked on KOMBIGLYZE XR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.